The long-acting phosphodiesterase inhibitor tadalafil does not influence athletes' V̇O2max, aerobic, and anaerobic thresholds in normoxia

International Journal of Sports Medicine

Volumn 29, Issue 2, 2008, Pages 110-115

  Di Luigi, Luigi ^a   Baldari, C ^a   Pigozzi, F ^a   Emerenziani, G P ^a   Gallotta, M C ^a   Iellamo, F ^b   Ciminelli, E ^a   Sgro P ^a   Romanelli, F ^c   Lenzi, A ^c   Guidetti, L ^a  

^a UNIVERSITY OF ROME FORO ITALICO   (Italy)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Doping; Erectile dysfunction; Exercise; Nitric oxide; PDE 5; Sport

Indexed keywords

LACTIC ACID; PLACEBO; TADALAFIL;

ADULT; AEROBIC EXERCISE; ANAEROBIC EXERCISE; ARTERIAL PRESSURE; ARTICLE; ATHLETE; BICYCLE ERGOMETER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; EXERCISE TOLERANCE; HEADACHE; HEART HEMODYNAMICS; HEART RATE; HUMAN; HUMAN EXPERIMENT; LACTATE BLOOD LEVEL; LUNG GAS EXCHANGE; MALE; OXYGEN CONSUMPTION; SYSTOLIC BLOOD PRESSURE;

ADULT; ANAEROBIC THRESHOLD; CARBOLINES; CROSS-OVER STUDIES; DELAYED-ACTION PREPARATIONS; DOUBLE-BLIND METHOD; EXERCISE TEST; HUMANS; ITALY; MALE; OXYGEN CONSUMPTION; PHOSPHODIESTERASE INHIBITORS; PHYSICAL ENDURANCE; PLACEBOS;

EID: 39149117328     PISSN: 01724622     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-965131     Document Type: Article

References (36)

1. Affuso F, Palmieri EA, Di Conza P, Guardasole V, Fazio S. Tadalafil improves quality of life and exercise tolerance in idiopathic pulmonary arterial hypertension. Int J Cardiol 2006; 108: 429-431
2. Arruda-Olson AM, Mahoney DW, Nehra A, Leckel M, Pellikka PA. Cardiovascular effects of sildenafil during exercise in men with known or probable coronary artery disease: a randomized crossover trial. JAMA 2002; 287: 719-725
3. Baldari C, Guidetti L. A simple method for individual anaerobic threshold as predictor of max lactate steady state. Med Sci Sports Exerc 2000; 32: 1798-1802
4. 2max, ventilatory and anaerobic thresholds in rhythmic gymnasts and young female dancers. J Sports Med Phys Fitness 2001; 41: 177-182
5. Beavo JA. Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms. Physiol Rev 1995; 75: 725-748
6. Bocchi EA, Guimaraes G, Mocelin A, Bacal F, Bellotti G, Ramires JF. Sildenafil effects on exercise, neurohormonal activation, and erectile dysfunction in congestive heart failure: a double-blind, placebo-controlled, randomized study followed by a prospective treatment for erectile dysfunction. Circulation 2002; 106: 1097-1103
7. Borg GA. Psychophysical bases of perceived exertion. Med Sci Sports Exerc 1982; 14: 377-381
8. Cohen-Solal A, Barnier P, Pessione F, Seknadji P, Logeart D, Laperche T, Gourgon R. Comparison of the long term prognostic value of peak exercise oxygen pulse and peak oxygen uptake in patients with chronic heart failure. Heart 1997; 78: 572-576
9. 2max criteria: discontinuous versus continuous protocols. Med Sci Sports Exerc 1997; 29: 273-278
10. Esposito K, Giugliano F, Di Palo C, Giugliano G, Marfella R, D'Andrea F, D'Armiento M, Giugliano D. Effect of lifestyle changes on erectile dysfunction in obese men: a randomized controlled trial. JAMA 2004; 291: 2978-2984
11. Francis SH, Corbin JD. Molecular mechanisms and pharmacokinetics of phosphodiesterase-5 antagonists. Curr Urol Rep 2003; 4: 457-465
12. Ghofrani HA, Reichenberger F, Kohstall MG, Mrosek EH, Seeger T, Olschewski H, Seeger W, Grimminger F. Sildenafil increased exercise capacity during hypoxia at low altitudes and at Mount Everest base camp: a randomized, double-blind, placebo-controlled crossover trial. Ann Intern Med 2004; 141: 169-177
13. Ghofrani HA, Voswinckel R, Reichenberger F, Olschewski H, Haredza P, Karadas B, Schermuly RT, Weissmann N, Seeger W, Grimminger F. Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension: a randomized prospective study. J Am Coll Cardiol 2004; 44: 1488-1496
14. Goto C, Higashi Y, Kimura M, Noma K, Hara K, Nakagawa K, Kawamura M, Chayama K, Yoshizumi M, Nara I. Effects of different intensities of exercise on endothelium-dependent vasodilation in humans: role of endothelium-dependent nitric oxide and oxidative stress. Circulation 2003; 108: 530-535
15. Guidetti L, Musulin A, Baldari C. Physiological factors in middleweight boxing performance. J Sports Med Phys Fitness 2002; 42: 309-314
16. Hagan RD, Smith MG. Pulmonary ventilation in relation to oxygen uptake and carbon dioxide production during incremental load work. Int J Sports Med 1984; 5: 193-197
17. Hollmann W. 42 years ago-development of the concepts of ventilatory and lactate threshold. Sports Med 2001; 31: 315-320
18. Hornig B, Maier V, Drexler H. Physical training improves endothelial function in patients with chronic heart failure. Circulation 1996; 93: 210-214
19. Hsu AR, Barnholt KE, Grundmann NK, Lin JH, McCallum SW, Frielander AL. Sildenafil improves output and exercise performance during acute hypoxia, but not in normoxia. J Appl Physiol 2006; 100: 2031-2040
20. Iemitsu M, Miyauchi T, Maeda S, Yuki K, Kobayashi T, Kumagai Y, Shimojo N, Yamaguchi I, Matsuda M. Intense exercise causes decrease in expression of both endothelial NO synthase and tissue NOx level in hearts. Am J Physiol 2000; 279: R951-R959
21. Jackson G. Hemodynamic and exercise effects of phosphodiesterase 5 inhibitors. Am J Cardiol 2005; 96: 32M-36M
22. Kim NN. Phosphodiesterase type 5 inhibitors: a biochemical and clinical correlation survey. Int J Impot Res 2003; 15: S13-S19
23. Kloner RA. Novel phosphodiesterase type 5 inhibitors: assessing hemodynamic effects and safety parameters. Clin Cardiol 2004; 27: 120-125
24. Lavie CJ, Milani RV, Mehra MR. Peak oxygen pulse and prognosis in chronic heart failure. Am J Cardiol 2004; 93: 588-593
25. Maeda S, Tanabe T, Otsuki T, Sugawara J, Iemitsu M, Miyauchi T, Kuno S, Ajisaka R, Matsuda M. Moderate regular exercise increases basal production of nitric oxide in elderly women. Hypertens Res 2004; 27: 947-953
26. McCullough AR. An update on the PDE-5 inhibitors (PDE-5i). J Androl 2003; 24: S52-S58
27. Metra M, Raddino R, Dei Cas L, Visioli O. Assessment of peak oxygen consumption, lactate and ventilatory thresholds and correlation with resting and exercise hemodynamic data in chronic congestive heart failure. Am J Cardiol 1990; 65: 1127-1133
28. O'Sullivan SE. The effects of exercise training on markers of endothelial function in young healthy men. Int J Sports Med 2003; 24: 404-409
29. Patterson D, Kloner R, Effron M, Emmick J, Bedding A, Warner M, Mitchell M, Braat S, MacDonald T. The effect of tadalafil on the time to exercise-induced myocardial ischaemia in subjects with coronary artery disease. Br J Clin Pharmacol 2005; 60: 459-468
30. Rakobowchuk M, McGowan CL, de Groot PC, Hartman JW, Phillips SM, MacDonald MJ. Endothelial function of young healthy males following whole body resistance training. J Appl Physiol 2005; 98: 2185-2190
31. Rhoden EL, Teloken C, Sogari PR, Vargas Souto CA. The use of the simplified international index of erectile function (IIEF-5) as a diagnostic tool to study the prevalence of erectile dysfunction. Int J Impot Res 2002; 14: 245-250
32. Ricart A, Maristany J, Fort N, Leal C, Pages T, Viscor G. Effects of sildenafil on the human response to acute hypoxia and exercise. High Alt Med Biol 2005; 6: 43-49
33. Richalet JP, Gratadour P, Robach P, Pham I, Dechaux M, Joncquiert-Latarjet A, Mallard P, Brugniaux J, Cornolo J. Sildenafil inhibits altitude-induced hypoxemia and pulmonary hypertension. Am J Respir Crit Care Med 2005; 171: 275-281
34. Smith KM, Romanelli F. Recreational use and misuse of phosphodiesterase 5 inhibitors. J Am Pharm Assoc 2005; 45: 63-72
35. Stanopoulos I, Hatzichristou D, Tryfon S, Tzortzis V, Apostolidis A, Argyropoulou P. Effects of sildenafil on cardiopulmonary responses during stress. J Urol 2003; 169: 1417-1421
36. Zusman RM, Morales A, Glasser DB, Osterloh IH. Overall cardiovascular profile of sildenafil citrate. Am J Cardiol 1999; 83: 35C-44C